Aclaris Therapeutics, Inc. (ACRS) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Feb 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Aclaris Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Aclaris Therapeutics, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
+11.50%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Turned Positive
GEMINI
Continuing Negative
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Aclaris Therapeutics, Inc. actually do?
Answer:
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Leveraging its proprietary KINect drug discovery platform, the company aims to identify and advance molecules with superior target affinity, specificity, and potency. Its pipeline includes bosakitug, an anti-TSLP monoclonal antibody for atopic dermatitis and other indications, and ATI-2138, an oral covalent ITK/JAK3 inhibitor for T cell-mediated autoimmune diseases. Aclaris also has programs for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, and ATI-9494, an oral covalent ITK inhibitor. The company seeks third-party partnerships to further develop and commercialize its product candidates.
Question:
What are Aclaris Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is generated from contract research services and licensing agreements, which include upfront fees, royalties, and milestone payments from third-party collaborations.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required